Article
The evolving genomic classification of lung cancer.
The Journal of pathology - 1 Jan 2014
Shames David S, Wistuba Ignacio I
Abstract excerpt
EGFR gene mutations and ALK gene fusions are well-characterized molecular targets in NSCLC. Activating alterations in a variety of potential oncogenic driver genes have also been identified in NSCLC, including ROS1, RET, MET, HER2, and BRAF. Together with EGFR and ALK, these mutations account for ∼20% of NSCLCs. The identification of these oncogenic drivers has led to the design of rationally targeted therapies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.